Imaging of sigma1 receptors in the human brain using PET and [11C]SA4503

Central Nervous System Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 190-196

  Toyohara, Jun ^a,b   Sakata, Muneyuki ^a   Ishiwata, Kiichi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Brain; Positron emission tomography; SA4503; Sigma1 receptor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE C 11; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 2BETA CARBOMETHOXY 3BETA (4 FLUOROPHENYL)TROPANE C 11; 6 FLUORODOPA F 18; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OPIATE AGONIST; PAROXETINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN UPTAKE INHIBITOR; SIGMA 1 OPIATE RECEPTOR; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; 1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

AGING; ALZHEIMER DISEASE; BRAIN; CEREBELLUM; COGNITIVE DEFECT; FRONTAL LOBE; HUMAN; KINETICS; MENTAL DISEASE; NEUROIMAGING; NONHUMAN; OCCIPITAL LOBE; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOPHARMACOLOGY; PUTAMEN; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; TEMPORAL LOBE; THALAMUS; VALIDITY; ANIMAL; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; METABOLISM; METHODOLOGY; PHYSIOLOGY; SCINTISCANNING; WHOLE BODY COUNTING;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; WHOLE-BODY COUNTING;

EID: 69249137822     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871524910909030190     Document Type: Review

References (36)

1. Hayashi, T.; Su, T.P. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs, 2004, 18(5), 269-284.
2. 1 receptor ligand. Expert. Opin. Ther. Targets, 2008, 12(1), 45-58.
3. Hashimoto, K.; Ishiwata, K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des., 2006, 12(30), 3857-3876. (Pubitemid 44560699)
4. Weissman, A.D.; Su, T.P.; Hedreen, J.C.; London, E.D. Sigma receptors in post-mortem human brains. J. Pharmacol. Exp. Ther., 1988, 247(1), 29-33.
5. Shibuya, H.; Mori, H.; Toru, M. Sigma receptors in schizophrenic cerebral cortices. Neurochem. Res., 1992, 17(10), 983-990.
6. Jansen, K.L.; Faull, R.L.; Storey, P.; Leslie, R.A. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res., 1993, 623(2), 299-302.
7. Stone, J.M.; Årstad, E.; Erlandsson, K.; Waterhouse, R.N.; Ell, P.J.; Pilowsky, L.N. [123I]TPCNE - A novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. Synapse, 2006, 60(2), 109-117. (Pubitemid 43878119)
8. 11C]SA4503. Neuroimage, 2007, 35(1), 1-8.
9. 1 receptor imaging. Ann. Nucl. Med., 2007, 21(9), 533-535.
10. 1 receptor quantification. Ann. Nucl. Med., 2008, 22(2),143-146.
11. Ishiwata, K.; Ishii, K.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Sakata, M.; Senda, N. Successive positron emission tomography measurement of cerebral blood flow and neuroreceptors in the human brain: an 11C-SA4503 study. Ann. Nucl. Med., 2008, 22(5), 411-416. (Pubitemid 351938516)
12. Mishina, M.; Ohyama, M.; Ishii, K.; Kitamura, S.; Kimura, Y.; Oda, K.; Kawamura, K.; Sasaki, T.; Kobayashi, S.; Katayama, Y.; Ishiwata, K. Low density of sigma1 receptors in early Alzheimer's disease. Ann. Nucl. Med., 2008, 22(3), 151-156. (Pubitemid 351729624)
13. Mishina, M.; Ishiwata, K.; Ishii, K.; Kitamura, S.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Sakayori, O.; Hamamoto, M.; Kobayashi, S.; Katayama, Y. Function of sigma1 receptors in Parkinson's disease. Acta Neurol. Scand., 2005, 112(2), 103-107. (Pubitemid 41003370)
14. 2-like receptors. Ann. Nucl. Med., 2006, 20(8), 569-573.
15. 11C]SA4503. Biol. Psychiatry, 2007, 62(8), 878-883.
16. 11C]SA4503: a feasibility study. J. Nucl. Med., 2004, 45(11), 1939-1946.
17. Mash, D.C.; Zabetian, C.P. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse, 1992, 12(3), 195-205.
18. 11C-methyl]-( - )-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab., 1990, 10(5), 740-747.
19. Lammertsma, A.A.; Hume, S.P. Simplified reference tissue model for PET receptor studies. Neuroimage, 1996, 4(3), 153-158. (Pubitemid 27024284)
20. 3H]DTG are elevated in aged Fischer-344 x Brown Norway (F1) rats. Synapse, 2000, 35(4), 311-313.
21. 1 receptors in the rat brain. Ann. Nucl. Med., 2003, 17(1), 73-77.
22. Kawamura, K.; Kimura, Y.; Tsukada, H.; Kobayashi, T.; Nishiyama, S.; Kakiuchi, T.; Ohba, H.; Harada, N.; Matsuno, K.; Ishii, K.; Ishiwata, K. An increase of sigma1 receptors in the aged monkey brain. Neurobiol. Aging, 2003, 24(5), 745-752. (Pubitemid 37288872)
23. 3H]-pentazocine binding sites in post-mortem human frontal cortex. J. Neural. Transm., 1996, 103(1-2), 45-53.
24. 1 receptor agonists. Drug News Perspect., 2002, 15(10), 617-625.
25. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39(6), 889-909.
26. 11C]beta-CFT in early Parkinson's disease. Synapse, 1995, 21(2), 97-103.
27. 11C]raclopride. J. Neurol. Sci., 1995, 132(2), 156-161.
28. 3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem. Int., 1998, 33(1), 29-34.
29. Gelb, D.J.; Oliver, E.; Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol., 1999, 56(1), 33-39. (Pubitemid 29046907)
30. 1 receptor in the adult rat central nervous system. Neuroscience, 2000, 97(1), 155-170.
31. Lee, C.S.; Samii, A.; Sossi, V.; Ruth, T.J.; Schulzer, M.; Holden, J.E.; Wudel, J.; Pal, P.K.; de la Fuente-Fernandez, R. ; Calne, D.B. ; Stoessel, A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol., 2000, 47(4), 493-503.
32. Kasper, S.; Tauscher, J.; Kufferle, B.; Barnas, C.; Pezawas, L.; Quiner, S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 1999, 249(Suppl 4), 83-89.
33. Frieboes, R.M.; Murck, H.; Antonijevic, I.; Kraus, T.; Hinze-Selch, D.; Pollmächer, T.; Steiger, A. Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls. Psychopharmacology (Berl), 1999, 141(1), 107-110. (Pubitemid 29193302)
34. Narita, N.; Hashimoto, K.; Tomitaka, S.; Minabe, Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol., 1996, 307(1), 117-119. (Pubitemid 26226293)
35. Hashimoto, K.; Fujita, Y.; Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology, 2007, 32(3), 514-521. (Pubitemid 46271046)
36. Suhara, T.; Takano, A.; Sudo, Y.; Ichimiya, T.; Inoue, M.; Yasuno, F.; Ikoma, Y.; Okubo, Y. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch. Gen. Psychiatry, 2003, 60(4), 386-391. (Pubitemid 36402999)